- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | MSD, Eisai abandon combination trial in liver cancer | ||
| Mi | BridgeBio two for two as rare disease drug aces ph3 trial | ||
| Mi | Specialty meds lift GSK's outlook in Walmsley's swan song | ||
| Mi | Falling flu vaccine sales in US stall CSL's Seqirus spinout | ||
| Mi | Lilly partners NVIDIA to build 'most powerful' supercomputer | ||
| Di | Texas sues J&J, Kenvue over Tylenol autism claim | ||
| Di | Campaign seeks to plug HIV care gap for UK women | ||
| Di | MapLight shares track up after $251m IPO | ||
| Di | GSK strikes again, adding COPD candidate in $745m deal | ||
| Di | Novartis' new drugs outweigh Entresto decline in Q3 | ||
| Mo | CRISPR biotech Intellia plummets as trial paused for safety | ||
| Mo | Organon CEO resigns over 'improper' contraceptive sales | ||
| Mo | As Blenrep returns, GSK adds another ADC to cancer pipeline | ||
| Mo | Pressure rises on Novo as Innovent drug tops Ozempic | ||
| Mo | Novartis makes $12bn wager on RNA drugs with Avidity buy | ||
| Fr | Chugai buys 'Asia lag' firm Renalys for $98m upfront | ||
| Fr | AZ, Organon fall foul of UK's code on pharma promotion | ||
| Fr | Bayer's prostate cancer drug Nubeqa cleared for NHS use | ||
| Fr | ICER says US new drug launch prices have risen sharply | ||
| Fr | GSK's Blenrep's back in US, but with a narrower label | ||
| 23.10. | George's triple therapy for hypertension hits mark in stroke | ||
| 23.10. | Google claims quantum advance could speed up drug discovery | ||
| 23.10. | Moderna drops mRNA jab for CMV after phase 3 fail | ||
| 23.10. | Alector ditches GSK-partnered dementia drug and cuts staff | ||
| 22.10. | Alkermes bets $2.1bn on Avadel and its narcolepsy drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .